You are here

STADA Pharmaceuticals Launches Web Site On Rheumatoid Arthritis and Rheumatrex® Dose Pack™

CRANBURY, N.J., July 13 /PRNewswire-FirstCall/ -- STADA Pharmaceuticals, Inc. has launched a content-rich, interactive web site, http://www.rheumatrex.info/, for rheumatoid arthritis patients, caregivers, and health care professionals. The web site provides comprehensive information about rheumatoid arthritis, tools for improving patient compliance and supporting treatment, and information about Rheumatrex® Dose Pack™ (methotrexate sodium tablets).

"We developed the web site to support patients and physicians in treating this chronic, potentially debilitating disease, and to encourage patient compliance, which is a significant problem with methotrexate," said Angel Biaggi, Vice President of Marketing at STADA Pharmaceuticals. "The site is an example of STADA's commitment to improve arthritis treatment by providing new products and supportive, patient-friendly services. We intend to expand our product line in arthritis and other rheumatic diseases and become a valuable resource for physicians and patients."

The extensive interactive web site educates visitors about rheumatoid arthritis. It describes its symptoms, diagnostic procedures, and available treatments, including drug therapy, diet and exercise, and answers most commonly asked questions. It serves as a primer for newly diagnosed patients and a supportive tool for medical professionals. The site also provides downloadable brochures for patients and providers, who can share the easy-to- understand information with patients.

Rheumatrex.info enables patients taking Rheumatrex® Dose Pack™ to register for the COPE (COmpliance and Patient Empowerment) program. Registrants can then access a range of interactive tools, including a scheduler, which enables them to keep track of all their doctor's appointments and other related appointments, such as lab tests, to maintain a record of Rheumatrex and other medications taken, and to record their exercise and diet regimen. Patients can also register to receive real-time weekly reminders to take their Rheumatrex, delivered by e-mail or a text message to their mobile phones. "We are truly delighted to offer patients the real-time, state-of- the-art reminders to help them adhere to the treatment regimen," said Mr. Biaggi. The site also features a health assessment questionnaire to help patients and their healthcare providers to monitor their progress.

Rheumatrex.info supports healthcare providers with educational materials to be shared with their patients and with tools to help improve patience compliance. It also enables them to order samples on line and allows them to learn about the product and support program enhancements offered by STADA.

About Rheumatrex®

Rheumatrex® Dose Pack™ (methotrexate sodium) is a once-weekly disease-modifying anti-rheumatic drug (DMARD) for moderate and severe rheumatoid arthritis. Since compliance is a significant issue with methotrexate, STADA Pharmaceuticals recently relaunched Rheumatrex (which it acquired from Wyeth) in compliance-friendly dose packs. The product is accompanied by a comprehensive patient compliance and education program. As a low-dosage oral methotrexate, Rheumatrex® is an aggressive treatment for rheumatoid arthritis that decreases symptoms, such as joint swelling and pain, and improves the long-term outcome. Methotrexate, the most widely prescribed treatment for this condition, is often an initial and maintenance treatment, prescribed alone or in combination with drugs such as nonsteroidal, anti- inflammatory drugs (NSAIDs) or corticosteroids. In low dosage, methotrexate is generally well tolerated, but may cause stomatitis, leukopenia, nausea, abdominal cramps, malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection.

About STADA Pharmaceuticals, Inc.

STADA Pharmaceuticals, Inc., headquartered in Cranbury, NJ, is the U.S. subsidiary of STADA Arzneimittel AG (OTC Pink Sheets: STDZF), in Bad Vilbel, Germany, a global pharmaceutical company with numerous subsidiaries worldwide. Founded in 1895 as a pharmacists' cooperative, STADA develops, manufactures and markets more than 300 prescription and over-the-counter pharmaceutical products worldwide, and ranks among the top generics suppliers in the world. With a rigorous focus on growth, STADA builds its product portfolio primarily through acquisitions and in-licensing in three core segments -- generic, branded and specialty pharmaceuticals. For more information about Rheumatrex®, visit http://www.rheumatrex.info/. For information about STADA Pharmaceuticals, visit http://www.stadausa.com/.

Recent Headlines

Overeager Use of Recommendations Creates Problems
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM